Abstract

Tumor-infiltrating lymphocytes (TILs) have emerged as a promising and dynamic area of research in the field of oncology, particularly in the context of early breast cancer. This paper delves into the prognostic and predictive utility of TILs, shedding light on their potential as valuable biomarkers for clinical decision-making. TILs are immune cells that infiltrate the tumor microenvironment, playing a pivotal role in the host immune response against cancer cells. In recent years, their presence and density within breast tumors have been associated with various clinical outcomes, offering valuable insights into patient prognosis and response to therapy. This review explores the current state of knowledge regarding the role of TILs in early breast cancer, summarizing key findings, methodologies, and clinical implications. By comprehensively assessing the available evidence, this paper aims to provide a clear understanding of how TILs can be harnessed to enhance patient management and treatment strategies, ultimately leading to improved outcomes for individuals facing the challenges of early breast cancer